Logo
x

Search

Subscribe Now

Galderma

Galderma Reports US FDA and EMA Filing Acceptances for Nemolizumab to Treat Prurigo Nodularis and Atopic Dermatitis; US FDA grants Priority Review in Prurigo Nodularis

Galderma Reports US FDA and EMA Filing Acceptances for Nemolizumab to Treat Prurigo Nodularis and Atopic Dermatitis; US FDA grants...

  • February 14, 2024
Galderma Receives Health Canada’s Approval for Restylane SHAYPE for Chin Augmentation

Galderma Receives Health Canada’s Approval for Restylane SHAYPE for Chin Augmentation

  • January 22, 2024
Galderma Presented P-III Trial (OLYMPIA 2) Results of Nemolizumab for the Treatment of Prurigo Nodularis at WCD 2023

Galderma Presented P-III Trial (OLYMPIA 2) Results of Nemolizumab for the Treatment of Prurigo Nodularis at WCD 2023

  • July 4, 2023
Galderma Presents P-III Trial (OLYMPIA 2) of Nemolizumab for Prurigo Nodularis at AAD 2023

Galderma Presents P-III Trial (OLYMPIA 2) of Nemolizumab for Prurigo Nodularis at AAD 2023

  • March 20, 2023
Galderma Reports Results of Nemolizumab in P-III (OLYMPIA 2) Trial for the Treatment of Prurigo Nodularis

Galderma Reports Results of Nemolizumab in P-III (OLYMPIA 2) Trial for the Treatment of Prurigo Nodularis

  • June 22, 2022
Insights+: The US FDA New Drug Approvals in April 2022

Insights+: The US FDA New Drug Approvals in April 2022

  • May 19, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.